Compare RELY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | CELC |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.2B |
| IPO Year | 2021 | 2017 |
| Metric | RELY | CELC |
|---|---|---|
| Price | $24.38 | $58.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $32.11 | ★ $156.91 |
| AVG Volume (30 Days) | ★ 3.0M | 1.3M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.16 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $1,635,147,000.00 | N/A |
| Revenue This Year | $21.52 | N/A |
| Revenue Next Year | $19.42 | $1,322.81 |
| P/E Ratio | $20.83 | ★ N/A |
| Revenue Growth | ★ 29.37 | N/A |
| 52 Week Low | $12.08 | $53.54 |
| 52 Week High | $27.48 | $151.02 |
| Indicator | RELY | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 27.14 |
| Support Level | $22.54 | N/A |
| Resistance Level | $24.87 | $118.53 |
| Average True Range (ATR) | 0.83 | 4.68 |
| MACD | 0.31 | -1.06 |
| Stochastic Oscillator | 80.57 | 14.51 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated from transaction fees charged to customers, and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.